Lubiprostone for the Treatment of Adults with Constipation and Irritable Bowel Syndrome
- 550 Downloads
Chronic constipation and IBS-C are two of the most common functional bowel disorders encountered by primary care providers and gastroenterologists, affecting up to 27% of the population in Western countries [1, 2, 3, 4]. The treatment of these disorders is often empiric and most current therapies are indicated for episodic constipation. Over time, most patients become refractory to one or more laxatives. Lubiprostone (Amitiza) has been approved by the US Food and Drug Administration (FDA) for the treatment of chronic-idiopathic constipation . It is an oral bicyclic fatty acid that selectively activates type 2 chloride channels in the apical membrane of the intestinal epithelial cells, hence stimulating chloride secretion, along with passive secretion of sodium and water, inducing peristalsis and laxation, without stimulating gastrointestinal smooth muscle. Several trials have shown it to be effective in the treatment of chronic idiopathic constipation, and recently also IBS-C. It has little systemic absorption and almost free of any serious adverse effects, however, occasionally can cause nausea. Based on the available evidence, it is reasonable to conclude that lubiprostone should be added to the short list of evidence-based pharmacotherapies for chronic constipation and IBS-C. Given the overlap between chronic constipation and IBS-C, clinicians can consider two strategies when deciding on the initial dose of lubiprostone. Based on current product labeling, it is recommended that 8 μg bid be started in patients with IBS-C whereas 24 μg bid be used in those with chronic constipation. Thus far, lubiprostone offers a novel approach to our therapeutic armamentarium, however, there is a need for more drugs with different mechanisms of action, in order to treat constipation that is often multifunctional.
KeywordsLubiprostone IBS-C Chronic idiopathic constipation Treatment Chloride channels (ClCs) Clinical efficacy Safety and tolerability
Dr. Satish Rao is supported by NIH grant RO1 DK 57100-05.
Conflict of interest
The authors disclose no conflicts.
- 8.Longstreth G, Thompson WG, Chey WD, et al. Functional bowel disorders. In: Drossman DA, Corazziari E, Delvaux M, et al., eds. Rome III: The Functional Gastrointestinal Disorders, First edn. McLean: Degnon Associates; 2006:487–555.Google Scholar
- 35.Thompson WG, Longstreth G, Drossman DA, Heaton K, Irvine EJ, Muller-Lissner S. Book chapter—functional bowel disorders and functional abdominal pain. In: Drossman DA, Corazziari E, Talley NJ, et al., eds. The Functional Gastrointestinal Disorders. 2nd ed. McLean: Degnon Associates; 2000:351–432.Google Scholar
- 51.Ueno R. Multiple, escalating, oral-dose study to assess the safety, tolerance and pharmacodynamic profile of lubiprostone in normal healthy volunteers. Neurogastroenterol Motil. 2005;17:A78.Google Scholar
- 54.Johanson JF, Panas R, Holland PC, et al. Long-term efficacy of lubiprostone for the treatment of chronic constipation. Gastroenterology. 2006;130:A317.Google Scholar
- 59.FDA Center for Drug Evaluation and Research (CDER)—April 2008.Google Scholar
- 64.Lubiprostone (Amitiza®) (Sucampo Pharmaceuticals. Chicago, IL: Bethesda & Takeda Pharmaceuticals of North America) —Package insert.Google Scholar